Status In progress
Decision Selected
Process TAG
ID number 1688


Key events during the development of the guidance:

Date Update
23 February 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab-relatlimab for untreated advanced or metastatic melanoma. Following information received from the company the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2022.
04 October 2021 Please note that following on from an update received from the company, more information on the timelines will be available in due course.
24 January 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual